Our work suggests that GSK3α- and ARIH1-activating agents, as well as EGFR inhibitors, are likely to stimulate anti-tumor immunity and therefore enhance existing cancer therapies by triggering the PD-L1 degradation pathway this work delineates. Here, GSK3A is linked to cancer.